News Precision Targeting of MYD88 Mutant DLBCL Using the Novel Combination of IRAKIMiD sand BCL2 Inhibition 12/12/22 Read more Discovery and characterization of potent degraders of IRAK4 and IMiD substrates for oncology indications 8/24/22 Read more Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiDSubstrates for Oncology 6/24/22 Read more Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications 6/7/22 Read more Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6/1/22 Read more 16th Annual International Conference on Malignant Lymphoma (ICML) Virtual Meeting, June 18 – 22, 2021 6/20/21 Read more American Association of Cancer Research (AACR) 2021 Annual Meeting, April 10-15, 2021 4/10/21 Read more 62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition, December 5-8, 2020 12/7/20 Read more 62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition, December 5-8, 2020 12/7/20 Read more IRAKIMiDs: A Single Small Molecule Approach to Developing Dual-Function Degraders for B Cell Lymphoma with Multiple Drivers 6/24/20 Read more
